Market Overview:
The global TDS market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in TDS devices. By type, the single-layer drug-in-adhesive segment is expected to account for the largest share of the global TDS market in 2018. By application, hospitals are expected to account for the largest share of the global TDS market in 2018.
Product Definition:
The importance of TDS is that it can provide a more controlled and consistent release of medication than other methods, such as oral administration. This is especially important for medications that need to be taken regularly over an extended period of time.
Single-layer Drug-in-Adhesive:
Single-layer drug-in-adhesive is a new technology that allows the controlled release of drugs on the skin. This technology has been developed to overcome drawbacks associated with traditional transdermal systems such as low rate of adhesion and absorption, difficulty in maintaining stability during storage and transportation, lack of patient compliance due to complexity in application techniques.
Multi-layer Drug-in-Adhesive:
Multi-layer drug-in-adhesive is a system that consists of two components, namely the adhesive layer and the drug. The multi-layered structure facilitates controlled delivery of drugs at various sites on the skin. It also helps in minimizing first pass metabolism when compared to conventional systems such as patches or films.
Application Insights:
Based on application, the global market is segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to increasing prevalence of chronic diseases such as diabetes and high number of surgeries. In addition, an increase in healthcare infrastructure has led to an increase in demand for transdermal delivery systems across hospitals globally.
The other application segment includes corporate wellness centers, home healthcare services and assisted living facilities among others. This segment is expected to grow at a significant rate over the forecast period due to rising geriatric population base worldwide coupled with growing awareness regarding pain management techniques among other age groups that require medication but cannot swallow it (for instance elderly people). Thus this trend is expected drive growth over the forecast period globally.
Increasing adoption of TDS by manufacturers for delivering medicine through patches that are adhesive or non-adhesive across various applications including clinics.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of key players and high adoption rate for advanced healthcare technologies. The region is expected to maintain its dominance over the forecast period due to increasing R&D investments by companies and universities for development of new products. Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure, growing medical tourism, and demand for cost-effective treatment options among others. In addition, government initiatives promoting healthy lifestyles are expected boost product demand in this region over the next eight years.
The European market also held a significant share in terms of revenue generation as major manufacturers have set up their manufacturing facilities in Europe due to easy availability of raw materials such as aluminum hydroxide which acts as an excipient ingredient used across various TDSs manufactured by these companies.
Growth Factors:
- Increasing demand for minimally invasive and non-invasive procedures: The global TDS market is expected to grow at a CAGR of over 7% during the forecast period. This can be attributed to the increasing demand for minimally invasive and non-invasive procedures, which offer several benefits such as shorter recovery time, reduced pain, and minimal scarring.
- Rising prevalence of chronic diseases: The prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is on the rise globally. This is leading to an increase in the number of patients requiring long-term treatment, which is driving the growth of the TDS market.
- Technological advancements: The development of new technologies that enable efficient delivery of drugs through skin has led to an increase in adoption rates of TDS devices worldwide. This is helping fuel the growth prospects of this market segment during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
TDS(Transdermal Delivery Systems) Market Research Report
By Type
Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Others
By Application
Hospital, Clinic, Other
By Companies
Adhex Pharma, Harro Hofliger, Tesa Labtec, Toyochem, Teva Pharmaceutical, Pfizer, IBSA Group, Teikoku Seiyaku, Endo International, Hisamitsu, Mylan, Sorrento Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global TDS(Transdermal Delivery Systems) Market Report Segments:
The global TDS(Transdermal Delivery Systems) market is segmented on the basis of:
Types
Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adhex Pharma
- Harro Hofliger
- Tesa Labtec
- Toyochem
- Teva Pharmaceutical
- Pfizer
- IBSA Group
- Teikoku Seiyaku
- Endo International
- Hisamitsu
- Mylan
- Sorrento Therapeutics
Highlights of The TDS(Transdermal Delivery Systems) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Single-layer Drug-in-Adhesive
- Multi-layer Drug-in-Adhesive
- Others
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the TDS(Transdermal Delivery Systems) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A TDS is a delivery system that uses transdermal technology to deliver medications directly to the skin. This allows for faster absorption and reduced side effects, compared to traditional oral or injectable medications.
Some of the key players operating in the tds(transdermal delivery systems) market are Adhex Pharma, Harro Hofliger, Tesa Labtec, Toyochem, Teva Pharmaceutical, Pfizer, IBSA Group, Teikoku Seiyaku, Endo International, Hisamitsu, Mylan, Sorrento Therapeutics.
The tds(transdermal delivery systems) market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. TDS(Transdermal Delivery Systems) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. TDS(Transdermal Delivery Systems) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. TDS(Transdermal Delivery Systems) Market - Supply Chain
4.5. Global TDS(Transdermal Delivery Systems) Market Forecast
4.5.1. TDS(Transdermal Delivery Systems) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. TDS(Transdermal Delivery Systems) Market Size (000 Units) and Y-o-Y Growth
4.5.3. TDS(Transdermal Delivery Systems) Market Absolute $ Opportunity
5. Global TDS(Transdermal Delivery Systems) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
5.3.1. Single-layer Drug-in-Adhesive
5.3.2. Multi-layer Drug-in-Adhesive
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global TDS(Transdermal Delivery Systems) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global TDS(Transdermal Delivery Systems) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global TDS(Transdermal Delivery Systems) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global TDS(Transdermal Delivery Systems) Demand Share Forecast, 2019-2026
9. North America TDS(Transdermal Delivery Systems) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
9.7.1. Single-layer Drug-in-Adhesive
9.7.2. Multi-layer Drug-in-Adhesive
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America TDS(Transdermal Delivery Systems) Demand Share Forecast, 2019-2026
10. Latin America TDS(Transdermal Delivery Systems) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
10.7.1. Single-layer Drug-in-Adhesive
10.7.2. Multi-layer Drug-in-Adhesive
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America TDS(Transdermal Delivery Systems) Demand Share Forecast, 2019-2026
11. Europe TDS(Transdermal Delivery Systems) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
11.7.1. Single-layer Drug-in-Adhesive
11.7.2. Multi-layer Drug-in-Adhesive
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe TDS(Transdermal Delivery Systems) Demand Share, 2019-2026
12. Asia Pacific TDS(Transdermal Delivery Systems) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
12.7.1. Single-layer Drug-in-Adhesive
12.7.2. Multi-layer Drug-in-Adhesive
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific TDS(Transdermal Delivery Systems) Demand Share, 2019-2026
13. Middle East & Africa TDS(Transdermal Delivery Systems) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa TDS(Transdermal Delivery Systems) Market Size and Volume Forecast by Type
13.7.1. Single-layer Drug-in-Adhesive
13.7.2. Multi-layer Drug-in-Adhesive
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa TDS(Transdermal Delivery Systems) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global TDS(Transdermal Delivery Systems) Market: Market Share Analysis
14.2. TDS(Transdermal Delivery Systems) Distributors and Customers
14.3. TDS(Transdermal Delivery Systems) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Adhex Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Harro Hofliger
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Tesa Labtec
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Toyochem
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Teva Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. IBSA Group
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teikoku Seiyaku
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Endo International
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hisamitsu
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Mylan
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sorrento Therapeutics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook